Xencor, Inc. (XNCR) Draws Bearish Attention After Forming Bearish Wedge Down Chart Pattern

Investors sentiment increased to 1.24 in 2018 Q4. Its up 0.33, from 0.91 in 2018Q3. It improved, as 15 investors sold Xencor, Inc. shares while 30 reduced holdings. 17 funds opened positions while 39 raised stakes. 46.47 million shares or 1.24% more from 45.91 million shares in 2018Q3 were reported.
Perceptive Advsr Limited Liability Com holds 196,810 shares or 0.26% of its portfolio. 435,066 are owned by Loomis Sayles Communications Limited Partnership. State Street owns 0% invested in Xencor, Inc. (NASDAQ:XNCR) for 1.40 million shares. Moreover, Charles Schwab Inv Mngmt has 0.01% invested in Xencor, Inc. (NASDAQ:XNCR). Natl Bank Of America Corp De owns 32,333 shares. 88,800 were reported by Swiss Commercial Bank. Hillsdale Invest Mngmt, Ontario – Canada-based fund reported 12,800 shares. The Minnesota-based First Light Asset Ltd Liability Com has invested 2.69% in Xencor, Inc. (NASDAQ:XNCR). Ecor1 Limited Liability invested in 989,018 shares. Rhenman Ptnrs Asset Mngmt Ab has 0.9% invested in Xencor, Inc. (NASDAQ:XNCR) for 218,537 shares. Bank & Trust Of Montreal Can accumulated 790 shares. Moreover, Invesco Limited has 0% invested in Xencor, Inc. (NASDAQ:XNCR). Manufacturers Life Ins Com The owns 28,781 shares for 0% of their portfolio. Bancshares Of New York Mellon Corp has invested 0% in Xencor, Inc. (NASDAQ:XNCR). Jpmorgan Chase And Com holds 0% or 246,162 shares in its portfolio.

Since March 15, 2019, it had 3 buys, and 0 sales for $1.74 million activity.

The stock of Xencor, Inc. (XNCR) formed a down wedge with $30.17 target or 6.00 % below today’s $32.10 share price. The 7 months wedge indicates high risk for the $1.81B company. If the $30.17 price target is reached, the company will be worth $108.54 million less.
Falling wedges are poor performers for bullish breakouts and are tricky moments to trade. Investors must be aware that the break even failure rate for up or down breakouts is: 11% and 15%. The average rise is 32% and the decline is 15%. The falling wedges has high throwback and pullback rate: 56%, 69% and the percent of wedges meeting target is not very high.

The stock decreased 4.34% or $1.45 during the last trading session, reaching $32.1. About 60,045 shares traded. Xencor, Inc. (NASDAQ:XNCR) has risen 6.90% since May 8, 2018 and is uptrending. It has outperformed by 2.53% the S&P500.

Analysts await Xencor, Inc. (NASDAQ:XNCR) to report earnings on May, 9 after the close. They expect $0.43 earnings per share, up 169.35 % or $1.05 from last year’s $-0.62 per share. XNCR’s profit will be $24.23 million for 18.66 P/E if the $0.43 EPS becomes a reality. After $-0.32 actual earnings per share reported by Xencor, Inc. for the previous quarter, Wall Street now forecasts -234.38 % EPS growth.

Xencor, Inc. (NASDAQ:XNCR) Ratings Coverage

Among 7 analysts covering Xencor (NASDAQ:XNCR), 6 have Buy rating, 1 Sell and 0 Hold. Therefore 86% are positive. Xencor had 11 analyst reports since December 7, 2018 according to SRatingsIntel. The firm has “Outperform” rating given on Friday, December 7 by Wedbush. The company was initiated on Thursday, March 14 by Raymond James. The firm has “Buy” rating by Wedbush given on Tuesday, February 26. The rating was maintained by Piper Jaffray with “Buy” on Tuesday, February 26. The stock of Xencor, Inc. (NASDAQ:XNCR) has “Buy” rating given on Wednesday, February 20 by Cantor Fitzgerald. The rating was maintained by Cantor Fitzgerald on Tuesday, February 26 with “Buy”. Nomura maintained it with “Sell” rating and $21 target in Thursday, March 21 report.

More notable recent Xencor, Inc. (NASDAQ:XNCR) news were published by: Fool.com which released: “3 Top Biotech Stocks to Buy Right Now – Motley Fool” on March 03, 2019, also Finance.Yahoo.com with their article: “Is Agree Realty Corporation (ADC) A Good Stock To Buy? – Yahoo Finance” published on April 30, 2019, Seekingalpha.com published: “Xencor, Inc. (XNCR) CEO Bassil Dahiyat on Q3 2018 Results – Earnings Call Transcript – Seeking Alpha” on November 05, 2018. More interesting news about Xencor, Inc. (NASDAQ:XNCR) were released by: Seekingalpha.com and their article: “Xencor up 12% on positive XmAb 14045 data – Seeking Alpha” published on November 01, 2018 as well as Nasdaq.com‘s news article titled: “Oversold Conditions For Xencor (XNCR) – Nasdaq” with publication date: October 05, 2018.

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. The company has market cap of $1.81 billion. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. It currently has negative earnings. The company's product candidates include XmAb5871, an immune inhibitor, which is in Phase II clinical trials for the treatment of autoimmune diseases; XmAb7195, an immune inhibitor that is in Phase I clinical for use in treating asthma and allergic diseases; XmAb14045, a bispecific oncology candidate, which is in phase I clinical trials for the treatment of acute myeloid leukemia; and XmAb13676 that is in phase I clinical trials for the treatment of B-cell malignancies.

Xencor, Inc. (NASDAQ:XNCR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.